{
    "data": [
        {
            "id": "2784515",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-29T09:06:19-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Labs Well Positioned For Success In 2015",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24112",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2784515-abbott-labs-well-positioned-for-success-in-2015"
            }
        },
        {
            "id": "2773645",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-22T15:12:33-05:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Buy And Hold Abbott Laboratories",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "67775",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2773645-buy-and-hold-abbott-laboratories"
            }
        },
        {
            "id": "2731325",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-04T13:42:38-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Labs Remains A No Touch For Me Right Now",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44001",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2731325-abbott-labs-remains-a-no-touch-for-me-right-now"
            }
        },
        {
            "id": "2715575",
            "type": "article",
            "attributes": {
                "publishOn": "2014-11-27T07:41:17-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Looking To Electrophysiology For Medical Device Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23479",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "145824",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2715575-abbott-looking-to-electrophysiology-for-medical-device-growth"
            }
        },
        {
            "id": "2703575",
            "type": "article",
            "attributes": {
                "publishOn": "2014-11-21T21:01:51-05:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Dividend Aristocrats In Focus Part 41: Abbott Laboratories",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "63883",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2703575-dividend-aristocrats-in-focus-part-41-abbott-laboratories"
            }
        },
        {
            "id": "2656345",
            "type": "article",
            "attributes": {
                "publishOn": "2014-11-07T10:51:40-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Looks Overvalued On A Fundamental Basis",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20411",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2656345-abbott-looks-overvalued-on-a-fundamental-basis"
            }
        },
        {
            "id": "2636515",
            "type": "article",
            "attributes": {
                "publishOn": "2014-11-05T11:52:40-05:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Update: Cardiovascular Systems Fiscal 2015 Q1 Earnings",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31461",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2636515-update-cardiovascular-systems-fiscal-2015-q1-earnings"
            }
        },
        {
            "id": "2595455",
            "type": "article",
            "attributes": {
                "publishOn": "2014-10-24T14:22:55-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Update: Abbott Posted Ordinary Third Quarter Earnings",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31461",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2595455-update-abbott-posted-ordinary-third-quarter-earnings"
            }
        },
        {
            "id": "2590595",
            "type": "article",
            "attributes": {
                "publishOn": "2014-10-23T15:53:01-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories: Analysis Of Q3 Earnings Miss",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25791",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2590595-abbott-laboratories-analysis-of-q3-earnings-miss"
            }
        },
        {
            "id": "2583795",
            "type": "article",
            "attributes": {
                "publishOn": "2014-10-22T11:50:49-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories' EPS Up 12% On Emerging Market Strength",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "63883",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "143548",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2583795-abbott-laboratories-eps-up-12-percent-on-emerging-market-strength"
            }
        },
        {
            "id": "2496415",
            "type": "article",
            "attributes": {
                "publishOn": "2014-09-15T15:00:45-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Update: Abbott To Invest $60 Million In An Intraocular Lens Plant In Malaysia",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31461",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "140910",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2496415-update-abbott-to-invest-60-million-in-an-intraocular-lens-plant-in-malaysia"
            }
        },
        {
            "id": "2487615",
            "type": "article",
            "attributes": {
                "publishOn": "2014-09-11T10:13:28-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Is Getting Expensive On A Fundamental Basis",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44001",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2487615-abbott-is-getting-expensive-on-a-fundamental-basis"
            }
        },
        {
            "id": "2464675",
            "type": "article",
            "attributes": {
                "publishOn": "2014-09-03T06:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories: An Emerging Markets Growth Play With Increasing Dividends",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "67985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "139830",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2464675-abbott-laboratories-an-emerging-markets-growth-play-with-increasing-dividends"
            }
        },
        {
            "id": "2441375",
            "type": "article",
            "attributes": {
                "publishOn": "2014-08-21T09:22:35-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott To Develop Portable Blood Tests For Concussions",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31461",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "139096",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2441375-abbott-to-develop-portable-blood-tests-for-concussions"
            }
        },
        {
            "id": "2414235",
            "type": "article",
            "attributes": {
                "publishOn": "2014-08-12T11:05:18-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Update: Cardiovascular Systems Earnings",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31461",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2414235-update-cardiovascular-systems-earnings"
            }
        },
        {
            "id": "2383485",
            "type": "article",
            "attributes": {
                "publishOn": "2014-08-05T14:49:36-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Abbott Labs Has Upside Potential",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "67815",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2383485-why-abbott-labs-has-upside-potential"
            }
        },
        {
            "id": "2325215",
            "type": "article",
            "attributes": {
                "publishOn": "2014-07-21T02:56:37-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Abbott's Stake In Mylan Will Be Value-Creative",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24491",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2325215-why-abbotts-stake-in-mylan-will-be-value-creative"
            }
        },
        {
            "id": "2319135",
            "type": "article",
            "attributes": {
                "publishOn": "2014-07-17T00:06:00-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories Declared Its 362nd Quarterly Dividend, But Earnings Were Mediocre",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44001",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2319135-abbott-laboratories-declared-its-362nd-quarterly-dividend-but-earnings-were-mediocre"
            }
        },
        {
            "id": "2316575",
            "type": "article",
            "attributes": {
                "publishOn": "2014-07-16T00:01:00-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Lab's Whisper Number Showing Some Confidence",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24051",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2316575-abbott-labs-whisper-number-showing-some-confidence"
            }
        },
        {
            "id": "2311895",
            "type": "article",
            "attributes": {
                "publishOn": "2014-07-13T02:13:29-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Is Abbott Laboratories Better Than Johnson & Johnson For Your Dividend Portfolio?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "63883",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2311895-is-abbott-laboratories-better-than-johnson-and-johnson-for-your-dividend-portfolio"
            }
        },
        {
            "id": "2299905",
            "type": "article",
            "attributes": {
                "publishOn": "2014-07-05T02:24:55-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Global Exploration For Acquisitions Should Help Abbott Labs In The Future",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44001",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2299905-global-exploration-for-acquisitions-should-help-abbott-labs-in-the-future"
            }
        },
        {
            "id": "2288693",
            "type": "article",
            "attributes": {
                "publishOn": "2014-06-26T16:54:04-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Is Undervalued With Significant Prospects In Vision Care",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31461",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "135833",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2288693-abbott-is-undervalued-with-significant-prospects-in-vision-care"
            }
        },
        {
            "id": "2284513",
            "type": "article",
            "attributes": {
                "publishOn": "2014-06-24T15:49:25-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories: Recent Emerging Market Acquisitions Boost Growth Profile",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2284513-abbott-laboratories-recent-emerging-market-acquisitions-boost-growth-profile"
            }
        },
        {
            "id": "2262953",
            "type": "article",
            "attributes": {
                "publishOn": "2014-06-11T05:35:20-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott And CFR Pharmaceutical - A Good Investment Combo",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56732",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "135052",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2262953-abbott-and-cfr-pharmaceutical-a-good-investment-combo"
            }
        },
        {
            "id": "2258723",
            "type": "article",
            "attributes": {
                "publishOn": "2014-06-09T08:47:21-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What 2 Macro Trends Are Propelling Abbott Laboratories?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "63883",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2258723-what-2-macro-trends-are-propelling-abbott-laboratories"
            }
        },
        {
            "id": "2241033",
            "type": "article",
            "attributes": {
                "publishOn": "2014-05-28T08:37:19-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott: A Worthwhile Investment",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56962",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "134464",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2241033-abbott-a-worthwhile-investment"
            }
        },
        {
            "id": "2224093",
            "type": "article",
            "attributes": {
                "publishOn": "2014-05-18T09:55:46-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories Acquires CFR Pharmaceuticals: What It Means And Why Shares Are Undervalued By 20%",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21820",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "133973",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2224093-abbott-laboratories-acquires-cfr-pharmaceuticals-what-it-means-and-why-shares-are-undervalued-by-20-percent"
            }
        },
        {
            "id": "2223623",
            "type": "article",
            "attributes": {
                "publishOn": "2014-05-16T22:16:15-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott's Dividend Is Well Supported By Earnings, But Is It A Buy?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44001",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2223623-abbotts-dividend-is-well-supported-by-earnings-but-is-it-a-buy"
            }
        },
        {
            "id": "2217203",
            "type": "article",
            "attributes": {
                "publishOn": "2014-05-14T10:23:22-04:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Or AbbVie - Which One Is Right For Your Dividend Income Dollars",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "64213",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2217203-abbott-or-abbvie-which-one-is-right-for-your-dividend-income-dollars"
            }
        },
        {
            "id": "2154953",
            "type": "article",
            "attributes": {
                "publishOn": "2014-04-22T15:53:03-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Expect Abbott To Raise Its 2014 Outlook Soon",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "30661",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2154953-expect-abbott-to-raise-its-2014-outlook-soon"
            }
        },
        {
            "id": "2146073",
            "type": "article",
            "attributes": {
                "publishOn": "2014-04-17T00:51:39-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Earnings And Revenue Decrease, But I'm Still Going To Buy Cautiously",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44001",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2146073-abbott-earnings-and-revenue-decrease-but-im-still-going-to-buy-cautiously"
            }
        },
        {
            "id": "2145243",
            "type": "article",
            "attributes": {
                "publishOn": "2014-04-16T15:28:21-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Earnings Preview: Emerging Markets And New Products Likely To Drive Sales",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23479",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2145243-abbott-earnings-preview-emerging-markets-and-new-products-likely-to-drive-sales"
            }
        },
        {
            "id": "2143773",
            "type": "article",
            "attributes": {
                "publishOn": "2014-04-16T02:38:55-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Labs Is A Solid Stock For Any Dividend Growth Portfolio",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44001",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2143773-abbott-labs-is-a-solid-stock-for-any-dividend-growth-portfolio"
            }
        },
        {
            "id": "2134193",
            "type": "article",
            "attributes": {
                "publishOn": "2014-04-09T17:29:47-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott: April's Long-Term Pick",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "52502",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "132199",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2134193-abbott-aprils-long-term-pick"
            }
        },
        {
            "id": "2126633",
            "type": "article",
            "attributes": {
                "publishOn": "2014-04-04T14:57:52-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories: This Company Has Potential To Expand Into Emerging Markets",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56962",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "131961",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2126633-abbott-laboratories-this-company-has-potential-to-expand-into-emerging-markets"
            }
        },
        {
            "id": "2089493",
            "type": "article",
            "attributes": {
                "publishOn": "2014-03-15T13:14:31-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Cardiovascular Systems' Orbital Atherectomy Could Be A Game Changer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31461",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "130878",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2089493-cardiovascular-systems-orbital-atherectomy-could-be-a-game-changer"
            }
        },
        {
            "id": "2087863",
            "type": "article",
            "attributes": {
                "publishOn": "2014-03-13T18:15:55-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "ModernGraham Quarterly Valuation Of Abbott",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23471",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2087863-moderngraham-quarterly-valuation-of-abbott"
            }
        },
        {
            "id": "2029911",
            "type": "article",
            "attributes": {
                "publishOn": "2014-02-19T01:43:44-05:00",
                "isLockedPro": false,
                "commentCount": 38,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Labs Should Be In Your Dividend Growth Portfolio",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "61751",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2029911-abbott-labs-should-be-in-your-dividend-growth-portfolio"
            }
        },
        {
            "id": "2009721",
            "type": "article",
            "attributes": {
                "publishOn": "2014-02-10T21:25:29-05:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Labs Has A Safe Dividend Yield",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44001",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2009721-abbott-labs-has-a-safe-dividend-yield"
            }
        },
        {
            "id": "1987541",
            "type": "article",
            "attributes": {
                "publishOn": "2014-02-03T01:38:02-05:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott: This Dividend Stock Reported 22% Earnings Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24349",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1987541-abbott-this-dividend-stock-reported-22-percent-earnings-growth"
            }
        },
        {
            "id": "1976001",
            "type": "article",
            "attributes": {
                "publishOn": "2014-01-29T09:14:31-05:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories: A Long-Term Play",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "57152",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "128417",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1976001-abbott-laboratories-a-long-term-play"
            }
        },
        {
            "id": "1966331",
            "type": "article",
            "attributes": {
                "publishOn": "2014-01-24T12:51:06-05:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott's Earnings Increase 22% Year Over Year, But Is It A Buy?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44001",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1966331-abbotts-earnings-increase-22-percent-year-over-year-but-is-it-a-buy"
            }
        },
        {
            "id": "1945981",
            "type": "article",
            "attributes": {
                "publishOn": "2014-01-15T04:53:35-05:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories: Cow Rated",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "55772",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1945981-abbott-laboratories-cow-rated"
            }
        },
        {
            "id": "1942491",
            "type": "article",
            "attributes": {
                "publishOn": "2014-01-13T13:29:20-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "I'm Holding Onto Dividend Paying Abbott Right Now",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44001",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1942491-im-holding-onto-dividend-paying-abbott-right-now"
            }
        },
        {
            "id": "1932331",
            "type": "article",
            "attributes": {
                "publishOn": "2014-01-07T11:24:27-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Will Abbott Perform Better In 2014?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "57152",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "127285",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1932331-will-abbott-perform-better-in-2014"
            }
        }
    ]
}